Literature DB >> 32782660

Burden of arrythmias in transgender patients hospitalized for gender-affirming surgeries.

Daniel Antwi-Amoabeng1, Rajkumar Doshi1, Devina Adalja2, Ashish Kumar3, Rupak Desai4, Raheel Islam1, Nageshwara Gullapalli1.   

Abstract

BACKGROUND: We sought to describe the burden of arrhythmias and their impact on in-hospital outcomes in transgender patients who underwent gender re-assignment surgery.
METHODS: The study utilized data from the National Inpatient Sample from January 2012 to September 2015.
RESULTS: 16 555 adult transgender patients were included in this study. A total of 610 adults developed arrhythmia out of which atrial fibrillation (N = 475, 2.87%) was the most frequent arrhythmia. In-hospital mortality increased substantially with arrhythmias.
CONCLUSIONS: New-onset arrythmias, while infrequent in the inpatient setting is associated with significantly higher in-hospital mortality and resource utilization.
© 2020 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society.

Entities:  

Keywords:  arrhythmia; atrial fibrillation; mortality; transgender

Year:  2020        PMID: 32782660      PMCID: PMC7411199          DOI: 10.1002/joa3.12360

Source DB:  PubMed          Journal:  J Arrhythm        ISSN: 1880-4276


INTRODUCTION

There is an increasing trend in the number of gender‐affirming surgeries in the United States, with mastectomy being the most frequently performed. Typically, patients receive gender‐affirming hormone (GAH) therapy before undergoing the surgical procedure. GAH have been shown to be associated with higher incidence of venous thrombosis, myocardial infractions, transient ischemic attacks in transgender patients than the general population. , This study aims to describe the incidence of arrhythmias in transgender patient who underwent gender‐affirming surgeries in the United States from 2012 to 2015 using the National Inpatient Sample (NIS).

METHODS

This study includes hospitalizations from the NIS which has been described elsewhere. , We included hospitalizations from January 2012 to September 2015 and identified hospitalizations using International Classifications of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) diagnostic codes. This study included previously utilized ICD‐9‐CM codes to identify study population (N = 18 525). We excluded patients below 18 years of age (N = 1970). New‐onset arrhythmias were identified using ICD‐9‐CM diagnosis codes in the secondary columns. This method and ICD‐9‐CM codes have been utilized in the past. , , We used Jonckheere‐Terpstra trend analysis for assessment of the trend in gender‐affirming surgeries from January 2012 to September 2015. The study was considered exempt from the institutional review board review as it utilized already available deidentified hospitalizations data.

RESULTS

We identified 16 555 transgender adult who were hospitalized for gender‐affirming surgeries from 2012 to 2015 and included in the final analysis (Table 1). The mean age of the population was 39.4 ± 15.3 years. We observed an increasing trend in the number of gender‐affirming surgeries performed during the period (P trend < .001, Figure 1B). The incidence of arrhythmia for the entire cohort was 3.68%. Arrhythmia occurred significantly more in those who historically identified as female (P = .0029), and those who were significantly older (Table 1). Fifty‐three percent of the patients historically identified as male. Although black patients represented 21% of the cohort, significantly more arrythmias occurred in this racial group (N = 430, P < .0001). Atrial fibrillation (N = 475, 2.87%) was the most common arrythmia followed by atrial flutter and ventricular tachycardia (Figure 1A). Both ventricular fibrillation and atrioventricular block occurred with equal frequency and were the least common arrythmias (n = 15 each, 0.09%). The incidence of arrhythmia was highest in patients who had their surgery in hospitals located in the West of the country. The mean length of stay was 6.5 days in those with arrhythmia and was significantly longer than the 5.1 days in those without. Mean cost of hospitalization was about $11 000 in the no arrythmia group and $19 000 in the arrythmia group.
Table 1

Patient and hospital level characteristic of study population

Variable name

Without arrhythmia

N = 15 945 (%)

With arrhythmia

N = 610 (%)

P‐value
Age (years): mean age ± SD38.6 ± 14.859.8 ± 14.1<.001
Biological sex a
Female6200295.002
Male8600315
Race
Black2970430<.0001
White936070
Other3615110
Comorbidities
Cigarette smoking5335 (33.5)235 (38.5).009
Illicit drug use3650 (22.9)55 (9)<.001
Chronic alcohol use1790 (11.2)55 (9).09
Chronic lung disease3100 (19.4)215 (35.2)<.001
Hypertension3995 (25)380 (62.3)<.001
Diabetes1525 (9.6)155 (25.4)<.001
Chronic kidney disease620 (3.9)110 (18)<.001
Depression2315 (14.5)100 (16.4.20
Chronic liver disease800 (5)40 (6.6).09
Hospital region
West5160 (32.4)220 (36.1)<.001
Mid‐West3460 (21.7)150 (24.6)
North East4210 (26.4)125 (20.5)
South3115 (19.5)115 (18.9
Patient outcomes
All‐cause mortality55 (0.4)30 (5)<.001
Stroke70 (0.4)30 (5)<.001
Length of stay (mean days ± SD)5.1 ± 7.46.5 ± 6.4<.001
Cost of hospitalization (mean US$ ± SD)11 072 ± 17 68719 302 ± 21 430<.001

1145 missing biological sex. SD = standard deviation.

Figure 1

Panel A: Number of GAS performed in the United States from January 2012 to September 2015. P trend < .001. Panel B: Frequency of arrhythmia in transgender patients hospitalized for GAS from January 2012 to September 2015. GAS, gender‐affirming surgeries

Patient and hospital level characteristic of study population Without arrhythmia N = 15 945 (%) With arrhythmia N = 610 (%) 1145 missing biological sex. SD = standard deviation. Panel A: Number of GAS performed in the United States from January 2012 to September 2015. P trend < .001. Panel B: Frequency of arrhythmia in transgender patients hospitalized for GAS from January 2012 to September 2015. GAS, gender‐affirming surgeries

DISCUSSION

This study shows a significant increase in the number of gender‐affirming surgeries and associated arrhythmias. However, frequency of arrhythmia is similar to what we have seen in general population or those underwent noncardiac surgeries of the same age. It is unknown if these arrhythmias are because of conditions that pertain to the surgeries themselves, that is, the increased stress response, and if preexisting conditions make patients susceptible to specific arrhythmias. The most common arrhythmia in our population, atrial fibrillation (2.87%) is lower than the reported 4% incidence in the general surgery population. The finding that atrial fibrillation as the commonest arrythmia in our cohort, compares well with prior analyses using the NIS for various disease states. , , , It has been hypothesized that low testosterone in transgender females may increase the risk for atrial and ventricular arrhythmia. There is higher incidence of atrial fibrillation in postmenopausal women on estrogen replacement therapy. Taken together, these studies support a likely influence of GAH, which transgender patients generally take prior to undergoing GAS, on incidence of perioperative arrhythmias. Incident arrythmias may require increased surveillance, involvement of subspecialists and likely admission to intensive care units, which can affect length of hospital stay, cost of hospitalization, and in‐hospital mortality. Patients in the West region experienced significantly more arrythmia. We speculate that since three of the top five states with the most adults identifying as transgender are in West region (ie, Hawaii, California, and New Mexico) those patients are more likely to have undergone GAS and included in the study. Arrhythmia was also associated with over $8000 more in cost of hospitalization and this is significant. There was an excess 4.6% all‐cause mortality in those who experienced an arrythmia (NNH = 22). Limitations of this study stem from our use of the NIS database. Limitations inherent in this database include but not limited to inability to validate the diagnoses, lack of information on the specific cause of death, inability to distinguish if patients were male‐to‐female or female‐to‐male transgender, and medication use. We are unable to determine whether the arrhythmias were associated with the surgical procedures themselves or patients were more susceptible to arrhythmia because of the gender‐affirming hormones they may have taken. We do not have information of QT interval duration, which is significantly affected by hormone use and psychotropic medications. Finally, these arrhythmias may occur outside of the hospital which were not captured since our analysis is limited to the in‐patient setting only.

CONCLUSION

The overall prevalence of arrhythmias is similar to general population and risk does not seem to be elevated in this population undergoing gender‐affirming surgery in the inpatient setting. The most common arrythmia in this patient population was atrial fibrillation. New‐onset arrhythmias while rare, present significantly excess all‐cause mortality, longer length of hospitalization, and higher cost of care in transgender patients who had gender‐affirming surgeries.

CONFLICT OF INTEREST

The authors of declare no conflict of interest.
  14 in total

1.  Temporal Trends in Gender-Affirming Surgery Among Transgender Patients in the United States.

Authors:  Joseph K Canner; Omar Harfouch; Lisa M Kodadek; Danielle Pelaez; Devin Coon; Anaeze C Offodile; Adil H Haider; Brandyn D Lau
Journal:  JAMA Surg       Date:  2018-07-01       Impact factor: 14.766

2.  Incidence of arrhythmias and impact of permanent pacemaker implantation in hospitalizations with transcatheter aortic valve replacement.

Authors:  Rajkumar Doshi; Dean H Decter; Perwaiz Meraj
Journal:  Clin Cardiol       Date:  2018-05-10       Impact factor: 2.882

3.  Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study.

Authors:  K Wierckx; E Elaut; E Declercq; G Heylens; G De Cuypere; Y Taes; J M Kaufman; G T'Sjoen
Journal:  Eur J Endocrinol       Date:  2013-09-13       Impact factor: 6.664

Review 4.  Cardiac arrhythmias secondary to hormone therapy in trans women.

Authors:  Rachel Wamboldt; Sohaib Haseeb; Ashley Waddington; Adrian Baranchuk
Journal:  Expert Rev Cardiovasc Ther       Date:  2019-04-26

Review 5.  The Perioperative Care of the Transgender Patient.

Authors:  Luis Etienne Tollinche; Chasity Burrows Walters; Asa Radix; Michael Long; Larissa Galante; Zil Garner Goldstein; Yvonne Kapinos; Cindy Yeoh
Journal:  Anesth Analg       Date:  2018-08       Impact factor: 5.108

6.  Long-term evaluation of cross-sex hormone treatment in transsexual persons.

Authors:  Katrien Wierckx; Sven Mueller; Steven Weyers; Eva Van Caenegem; Greet Roef; Gunter Heylens; Guy T'Sjoen
Journal:  J Sex Med       Date:  2012-08-20       Impact factor: 3.802

7.  Stress hormone responses to major intra-abdominal surgery during and immediately after sevoflurane-nitrous oxide anaesthesia in elderly patients.

Authors:  K Furuya; R Shimizu; Y Hirabayashi; R Ishii; H Fukuda
Journal:  Can J Anaesth       Date:  1993-05       Impact factor: 5.063

8.  Postoperative arrhythmias in colorectal surgical patients: incidence and clinical correlates.

Authors:  S R Walsh; J E Oates; J A Anderson; S D Blair; C A Makin; C J Walsh
Journal:  Colorectal Dis       Date:  2006-03       Impact factor: 3.788

9.  Evaluation of the Incidence of New-Onset Atrial Fibrillation After Aortic Valve Replacement.

Authors:  Rajat Kalra; Nirav Patel; Rajkumar Doshi; Garima Arora; Pankaj Arora
Journal:  JAMA Intern Med       Date:  2019-08-01       Impact factor: 21.873

10.  The burden of cardiac arrhythmias in sarcoidosis: a population-based inpatient analysis.

Authors:  Rupak Desai; Kiranmayi Kakumani; Hee Kong Fong; Bhrugesh Shah; Daniyal Zahid; Dipen Zalavadia; Rajkumar Doshi; Hemant Goyal
Journal:  Ann Transl Med       Date:  2018-09
View more
  1 in total

Review 1.  Sexual Dimorphisms, Anti-Hormonal Therapy and Cardiac Arrhythmias.

Authors:  Virginie Grouthier; Melissa Y Y Moey; Estelle Gandjbakhch; Xavier Waintraub; Christian Funck-Brentano; Anne Bachelot; Joe-Elie Salem
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.